Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 677

1.

Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.

Lázár V, Ecsedi S, Vízkeleti L, Rákosy Z, Boross G, Szappanos B, Bégány A, Emri G, Adány R, Balázs M.

Melanoma Res. 2012 Jun;22(3):202-14. doi: 10.1097/CMR.0b013e328352dbc8.

PMID:
22456166
2.

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V.

Magy Onkol. 2013 Jun;57(2):96-9. doi: MagyOnkol.2013.57.2.96. Epub 2013 May 20. Hungarian.

3.

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M.

Mod Pathol. 2009 Oct;22(10):1367-78. doi: 10.1038/modpathol.2009.109. Epub 2009 Jul 24.

4.

Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.

Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, Hemminki K, Schadendorf D, Kumar R.

Genes Chromosomes Cancer. 2010 Aug;49(8):733-45. doi: 10.1002/gcc.20785.

PMID:
20544847
5.

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A.

Melanoma Res. 2008 Feb;18(1):29-35. doi: 10.1097/CMR.0b013e3282f32517.

PMID:
18227705
6.

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J.

Eur J Cancer. 2012 Jan;48(1):94-100. doi: 10.1016/j.ejca.2011.06.056. Epub 2011 Jul 23.

PMID:
21788131
7.

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J.

Melanoma Res. 2006 Dec;16(6):471-8.

PMID:
17119447
8.

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G.

J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452. Epub 2012 May 21.

PMID:
22614978
9.

Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

Saldanha G, Potter L, Daforno P, Pringle JH.

Clin Cancer Res. 2006 Aug 1;12(15):4499-505.

10.

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

Lee JH, Choi JW, Kim YS.

Br J Dermatol. 2011 Apr;164(4):776-84. doi: 10.1111/j.1365-2133.2010.10185.x. Epub 2011 Mar 21.

PMID:
21166657
11.

Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.

Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Süsskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D.

Clin Cancer Res. 2013 Jun 15;19(12):3143-52. doi: 10.1158/1078-0432.CCR-13-0163. Epub 2013 Apr 30.

12.

Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.

Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J, Yasui K, Misawa-Furihata A, Kawakami Y, Inazawa J.

Oncogene. 2004 Nov 18;23(54):8796-804.

PMID:
15467732
13.

Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines.

Greshock J, Nathanson K, Medina A, Ward MR, Herlyn M, Weber BL, Zaks TZ.

Genes Chromosomes Cancer. 2009 May;48(5):419-28. doi: 10.1002/gcc.20651.

14.

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Omholt K, Platz A, Kanter L, Ringborg U, Hansson J.

Clin Cancer Res. 2003 Dec 15;9(17):6483-8.

15.

Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.

Yaman B, Akalin T, Kandiloğlu G.

Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.

PMID:
25357015
16.

The role of CCND1 alterations during the progression of cutaneous malignant melanoma.

Vízkeleti L, Ecsedi S, Rákosy Z, Orosz A, Lázár V, Emri G, Koroknai V, Kiss T, Ádány R, Balázs M.

Tumour Biol. 2012 Dec;33(6):2189-99. doi: 10.1007/s13277-012-0480-6. Epub 2012 Sep 23.

PMID:
23001925
17.

Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.

Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J.

J Natl Cancer Inst. 2003 Jun 4;95(11):790-8.

PMID:
12783933
18.

Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.

Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G.

Int J Cancer. 2004 Apr 10;109(3):377-84.

19.

NRAS and BRAF mutation frequency in primary oral mucosal melanoma.

Buery RR, Siar CH, Katase N, Gunduz M, Lefeuvre M, Fujii M, Inoue M, Setsu K, Nagatsuka H.

Oncol Rep. 2011 Oct;26(4):783-7. doi: 10.3892/or.2011.1385. Epub 2011 Jul 11.

PMID:
21750866
20.

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.

Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, André J, Dumaz N, Ortonne N.

Hum Pathol. 2013 Sep;44(9):1902-11. doi: 10.1016/j.humpath.2013.01.025. Epub 2013 May 9.

Supplemental Content

Support Center